Cover Image
Market Research Report
Product code 
923129

Non-injectable Insulin

Published: | BCC Research | 54 Pages | Delivery time: 1-2 business days

Price

Back to Top
Non-injectable Insulin
Published: January 22, 2020
BCC Research
Content info: 54 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents
  • List of Tables

Report Highlights:

This comprehensive report provides an in-depth assessment of the global market for non-injectable insulin. The report's key objective is to analyze areas of opportunities, key developments and the impact of this technology on industry, specifically the pharmaceutical, biotechnology and healthcare sectors. The analysis also reviews the adoption of non-injectable insulin in developed and emerging markets.

Report Scope:

The report provides a comprehensive summary of the Non-injectable insulin market, along with detailed profiles of key market players that include revenue product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges and opportunities. The report discusses strategies adopted by emerging market players, with recommendations for new market entrants. This research study discusses historical, current and potential market size. The report will help market players and new entrants make informed decisions about the production and export of goods and services. Organizations, distributors and exporters should find the information about market development and trends useful. The study segments the market according to applications and end uses. Geographical market analysis is provided for all major segments.

Report Includes:

  • An overview of the global market for non-injectable insulin
  • Analyses of market trends, with data from 2018, 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Information on recent major technical advances in different forms of non-injectable insulin
  • A look at the key areas of growth and adoption rate of non-injectable insulin among both commercial customers and regulatory authorities
  • Examination of strategies of the major players in the market and the impact of new technological developments
Product Code: PHM224A

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Future Market Potential and Investment Analysis
  • North America Will be the Largest and Fastest-Growing Market

Chapter 4: Market Breakdown by Form

  • Pills
  • Spray
  • Others (Film and Chewing Gum)

Chapter 5: Market Breakdown by Source

  • Synthetic Insulin
  • Semisynthetic Insulin

Chapter 6: Market Breakdown by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Rest of the World

Chapter 7: Competitive Landscape

Chapter 8: Company Profiles

  • ACCESS PHARMACEUTICALS INC. (ABEONA THERAPEUTICS INC.)
  • AERAMI THERAPEUTICS
  • BIOCON LTD.
  • BIODEL INC. (ALBIREO LTD.)
  • BIONOVA LIFESCIENCES
  • BOSTON THERAPEUTICS INC.
  • COROMED INC.
  • DIABETOLOGY LTD.
  • DIASOME PHARMACEUTICALS INC.
  • EMISPHERE TECHNOLOGIES INC.
  • GENEREX BIOTECHNOLOGY CORP.
  • MIDATECH PHARMA PLC
  • ORAMED PHARMACEUTICALS INC.
  • RANI THERAPEUTICS
  • SHREYA LIFE SCIENCES PVT. LTD.

List of Tables

  • Summary Table: Global Market for Non-injectable Insulin, by Region, Through 2024
    • Table 1: Other Products Related to Non-injectable Insulin
    • Table 2: Examples of Non-injectable Insulin Products
    • Table 3: Global Market for Non-injectable Insulin, by Form, Through 2024
    • Table 4: Global Market for Edible Insulin Pills, by Region, Through 2024
    • Table 5: Global Market for Insulin Sprays, by Region, Through 2024
    • Table 6: Global Market for Other Forms of Non-injectable Insulin, by Region, Through 2024
    • Table 7: Global Market for Non-injectable Insulin, by Source, Through 2024
    • Table 8: Global Market for Synthetic Non-injectable Insulin, by Region, Through 2024
    • Table 9: Global Market for Semisynthetic Non-injectable Insulin, by Region, Through 2024
    • Table 10: Global Market for Non-injectable Insulin, by Region, Through 2024
    • Table 11: Top 10 Countries with the Highest Prevalence of Diabetes Across the Globe, 2019
    • Table 12: North American Market for Non-injectable Insulin, by Form, Through 2024
    • Table 13: North American Market for Non-injectable Insulin, by Source, Through 2024
    • Table 14: Prevalence of Diabetes in North American Countries, 2010-2017
    • Table 15: Prevalence of Diabetes in North America, 2019-2045
    • Table 16: Prevalence of Diabetes in Europe, 2019-2045
    • Table 17: European Market for Non-injectable Insulin, by Form, Through 2024
    • Table 18: European Market for Non-injectable Insulin, by Source, Through 2024
    • Table 19: Existing National Diabetes Plans in Europe, by Country
    • Table 20: Prevalence of Diabetes in Asia-Pacific, 2019-2045
    • Table 21: Asia-Pacific Market for Non-injectable Insulin, by Form, Through 2024
    • Table 22: Asia-Pacific Market for Non-injectable Insulin, by Source, Through 2024
    • Table 23: Rest of the World Market for Non-injectable Insulin, by Form, Through 2024
    • Table 24: Rest of the World Market for Non-injectable Insulin, by Source, Through 2024

List of Figures

  • Summary Figure: Global Market for Non-injectable Insulin, by Region, 2018-2024
    • Figure 1: Global Prevalence of Diabetes in the 20-79 Year Age Group, 2011-2045*
    • Figure 2: Global Diabetes Prevalence, 2019-2045
    • Figure 3: Novo Nordisk Revenue Share, by Region, 2018
    • Figure 4: Eli Lilly Revenue Share, by Segment, 2018
    • Figure 5: Nektar Therapeutics Revenue Share, by Region, 2018